The primary goal of this research was to validate the final form of a patient-appraised survey that describes the occurrence and seriousness of non-motor fluctuations in patients with levodopa-treated Parkinson’s disease (PD; NoMoFA).

Patients with Parkinson’s disease were enrolled from 5 movement disorder centers across the US and Canada for this research. The researchers studied the internal consistency, floor and ceiling impacts, test-retest dependability, and simultaneous legitimacy of NoMoFA. Classical test and item response theory techniques informed item decrease, and the Delphi process produced a final questionnaire.

In this study, 200 patients and their care-providers took part (age, 66.4 ± 9.6; infection term: 9 ± 5.5 years; middle Hoehn and Yahr [H&Y] OFF: 3 [range, 15]; mean Unified Parkinson’s Disease Rating Scale (UPDRS) III ON score, 27.4 ± 14.9). The acceptance of the scale was satisfactory. There were floor impacts in 8 out of 28 items. Cronbach’s alpha was 0.894.

The NoMoFA is a valid and dependable 27-item self-administered assessment that captures both stationary and variable non-motor symptoms in Parkinson’s disease.

Reference link-